Company / Cash & Equivalents
cbdMD, Inc. Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$2.3M
FY2025
5-year range
$1.8M / $14.8M
FY2021-FY2025
Trend
-7.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 9 years, ranging from $34,258 in FY2017 to $15M in FY2021.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -13.6%.
Improved from $2M to $2M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -30.4%
- 5-Year CAGR
- -13.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -13.6%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 7.8% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 1.21 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.3M | -7.8% |
| FY2024 | $2.5M | +36.4% |
| FY2023 | $1.8M | -73.2% |
| FY2022 | $6.7M | -54.7% |
| FY2021 | $14.8M | +216.1% |
| FY2020 | $4.7M | +9.5% |
| FY2019 | $4.3M | +1406.6% |
| FY2018 | $284.2K | +729.7% |
| FY2017 | $34.3K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026